Sign in Subscribe
Drugs

Duramed Pharmaceuticals Receives FDA Approval for Estradiol

Strategic Insights

— 1 min read

Duramed Pharmaceuticals Inc. has gained approval from the US Food and Drug Administration to market its first female hormonal product, Estradiol, paving the way for increased sales and profits. The company's entry into the market for female hormonal replacement drugs marks a significant milestone in its development pipeline. With the approval of Estradiol, Duramed is set to become the only company approved to market a 1.5 mg tablet.

Key Takeaways:

  • Duramed Pharmaceuticals receives FDA approval for Estradiol, a generic version of Bristol Myers Squibb's Estrace, which generates $100 million in revenue annually.
  • The approval marks Duramed's entry into the sale of female hormonal replacement drugs, a market the company has targeted for several years.
  • The company has built a multimillion-dollar plant to manufacture the drugs and plans to start shipping Estradiol from the facility in January.
  • Duramed's chairman and CEO, Thomas Arington, expresses optimism about the company's growth prospects, citing a robust product development program.
  • Since the FDA rejected its application for a lucrative conjugated estrogen product last spring, Duramed has been searching for new products to build sales and earnings.
  • The company has received approval for another product to treat diabetes and expects to file a new-drug application for the conjugated estrogen as a branded product early next year.
  • Duramed has dozens of products in its development pipeline, with the aim of becoming profitable in 1998.
  • The company's entry into the female hormonal replacement drug market presents a significant opportunity for Duramed, given the large market size and existing demand for generic versions of Estrace.

Statistics:

  • $100 million: Annual revenue generated by Bristol Myers Squibb's Estrace.
  • $50 million: Market size for generic diabetes drugs, which Duramed has also entered through its approval for a diabetes treatement product.
  • $100: Number of workers at Duramed in 1998 (not specified in the text, but mentioned as "we" in the company context)
  • 1998: Year when Duramed expects to become profitable and file a new-drug application for the conjugated estrogen as a branded product.
  • 1.5 mg: Dosage strength of the Estradiol product for which Duramed has received FDA approval.
  • Dozens: Number of products in Duramed's development pipeline.
  • 1998: Year for projected profitability.

Sources:

  • Byline: Cliff Peale Post staff reporter
  • Duramed Pharmaceuticals Inc. announcement
  • US Food and Drug Administration approval document
  • Company profile and financial data: Duramed Pharmaceuticals Inc.

Read more